← Leaderboards
Lynda G Tussey
Vaxinnate Corporation
$1,451,127
Attributed
$2,602,253
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $754.1K · FY2008–16$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$2,602,253 · 3
By mechanism
R01$2,183,992 · 1
R43$300,000 · 1
R21$118,261 · 1
Top collaborators
- Ge Liu4 shared
Most similar at Vaxinnate Corporation
Same institution · by research overlap
- Ge Liu$1,151,127
- Albert Price$298,530
Others in their field
Top investigators on “West Nile Virus”
- Michael S. Diamond · University Of Pittsburgh At Pittsburgh$43,935,741
- Michael J Gale · University Of Texas Sw Med Ctr/Dallas$29,709,868
- Erol Fikrig · Yale University$26,966,074
- Mark K Slifka · Oregon Health And Science University$24,161,842
- Janko Nikolich-Zugich · University Of Arizona$23,732,936
- Ralph S Baric · University Of North Carolina Chapel Hill$15,308,520
Research focus
West Nile VirusNeutralizing AntibodyLinkVirusDengueSignal TransductionImmunogenicityLigandsSerotypingVaccinesFlavivirusAntigensImmune ResponseTlr5 GeneAdjuvantFlagellinLeadLifeAgonistDengue Shock SyndromeImmune SeraImmuneImmunityEquilibrium
Grant awards (5)
Development of a Recombinant Zika Virus Vaccine Based on Subunit Envelope (E) Amtigen Fused to a TLR5 Agonist (Flagellin)$118,261
R21 · FY2016 · AI
Development of a Recombinant Tetravalent Dengue Vaccine Based on a Subunit Envelo$754,080
R01 · FY2015 · AI
Development of a Recombinant Tetravalent Dengue Vaccine Based on a Subunit Envelo$683,222
R01 · FY2014 · AI
Development of a Recombinant Tetravalent Dengue Vaccine Based on a Subunit Envelo$746,690
R01 · FY2013 · AI
Development of a Tetravalent Dengue Vaccine that Links Innate and Adaptive Immuni$300,000
R43 · FY2008 · AI · contact PI